Endoscopic Remission

Biomarker

Related News

Risankizumab Data in Crohn’s Disease Show Remission, Durable Response and Low Switch Rates

May 05, 2026

Risankizumab data in Crohn’s disease showed 55% clinical remission at week 12 in AFFIRM, durable efficacy through 148 weeks in SEQUENCE, and the lowest 24-month switch rate in a U.S. claims analysis.

TREMFYA® Shows Sustained Remission in Ulcerative Colitis Through Week 140

Feb 21, 2026

Long-term data from the QUASAR extension study show TREMFYA® maintained clinical remission in over 80% of ulcerative colitis patients at Week 140, with more than half achieving endoscopic remission and no new safety concerns observed.